Longitudinal Imaging Biomarkers of Dementia with Lewy Bodies
What is the purpose of this study?
This study aims to uncover and track how brain changes evolve over time in individuals with Dementia with Lewy Bodies (DLB), including its earliest stages. By using a range of imaging techniques and biological markers, researchers hope to develop better ways to detect and treat DLB.
Who is a qualifying participant?
- Clinical diagnosis of probable DLB or mild cognitive impairment due to Lewy body disease (MCI-LB).
- Age 18 or older.
- Must have a reliable informant (e.g., family member or close friend) who interacts with the participant at least weekly.
- Can participate in MRI scanning.
What are we asking of you in this study?
Participants are asked to attend up to 6 study visits (baseline, 6 months, then annually from year 1 through year 4). During study visits, the following procedures will be performed:
- Imaging Assessments, including positron emission tomography (PET) scans to measure proteins (amyloid, tau), Dopamine transporter imaging (DaT-SPECT) to assess changes in dopamine levels, and MRI of the brain to assess structural changes. Some participants may also complete Polysomnography (PSG) to assess sleep patterns that can be affected in DLB.
- Clinical, Cognitive & Functional Evaluations, including neurological examination, cognitive assessments, and evaluation of core DLB symptoms, such as visual hallucinations, REM sleep behavior disorder (RBD), parkinsonism, and cognitive fluctuations.
- Biomarker Collections from blood draw and cerebrospinal fluid (lumbar puncture).